LDN

DRUG2 trials

Sponsors

Katy Peters, Stanford University

Conditions

Complex Regional Pain SyndromeMalignant Glioma

Phase 2

Low Dose Naltrexone for Glioma Patients

CompletedNCT01303835

Katy PetersMalignant Glioma

Start: 2011-05-31End: 2015-05-31Updated: 2015-07-17

Unknown Phase

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

RecruitingNCT02502162

Stanford UniversityComplex Regional Pain Syndrome

Start: 2015-06-30End: 2027-07-31Target: 120Updated: 2025-05-29

Related Papers

Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.

2022-01-105 citations